Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Infergen (interferon alfacon-1)
- sargramostim
Interactions between your drugs
sargramostim interferon alfacon-1
Applies to: sargramostim, Infergen (interferon alfacon-1)
ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.
MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.
References (4)
- (2002) "Product Information. Neupogen (filgrastim)." Amgen
- (2001) "Product Information. Leukine (sargramostim)." Immunex Corporation
- (2001) "Product Information. Stemgen (ancestim)." Amgen
- (2013) "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Epclusa
Epclusa treats chronic hepatitis C in adults and children 3+. This once-daily antiviral combines ...
Harvoni
Harvoni is used to treat hepatitis C virus (HCV) infections in adults and children aged 3 years and ...
Botox
Botox is used to treat chronic migraines, excessive sweating, bladder conditions, eye muscle ...
Mavyret
Mavyret (glecaprevir/pibrentasvir) is an oral combination medicine containing fixed doses of two ...
Sovaldi
Sovaldi (sofosbuvir) is used to treat chronic hepatitis C virus (HCV) infection. Includes Sovaldi ...
Pegasys
Pegasys is used to treat chronic hepatitis B or C. Learn about side effects, interactions and ...
Vosevi
Vosevi (sofosbuvir,velpatasvir and voxilaprevir) is used to treat chronic hepatitis C. Includes ...
Zepatier
Zepatier (elbasvir and grazoprevir) is used to treat chronic hepatitis C. Includes Zepatier side ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.